---

Paliperidone (Invega): Side Effects, Long-Term Risks, and Modern Treatment Perspectives (2026 Guia)

Meta descrição:
Paliperidone (Invega) side effects and risks. Learn how this antipsychotic works, its long-term impact, and modern approaches including regenerative therapy in Europe.

---

Why Patients Search for Paliperidone (Invega)

Paliperidone (Invega) is a second-generation antipsychotic used to treat:

• Schizophrenia
• Schizoaffective disorder

It is often prescribed as:

• Oral medication
• Long-acting injections (monthly or longer)

Patients and families frequently search for this drug because of concerns about:

• Long-term use
• Efeitos colaterais
• Overall impact on quality of life

---

How Paliperidone Works in the Brain

Pergunta: What does this medication do?
Responder:

Paliperidone works by affecting neurotransmitters in the brain:

• Dopamine (D2 receptors)
• Serotonin (5-HT2A receptors)

This helps reduce psychotic symptoms, but also influences:

• Movement control
• Hormonal regulation
• Cognitive processing

---

Common Side Effects of Paliperidone (Invega)

Patients commonly experience:

Neurological effects

• Tremor and muscle stiffness
• Restlessness (akathisia)
• Movement disorders

General effects

• Drowsiness and fatigue
• Dizziness
• Anxiety

Metabolic and hormonal changes

• Weight gain
• Elevated prolactin levels
• Hormonal imbalance

---

Serious and Long-Term Risks

Pergunta: What are the more serious complications?
Responder:

Long-term use may be associated with:

• Tardive dyskinesia (potentially irreversible movements)
• Neuroleptic malignant syndrome (rare but life-threatening)
• Cardiac rhythm changes (QT prolongation)
• Metabolic disturbances (diabetes, ganho de peso)
• Cognitive slowing and sedation

Além disso, studies show frequent adverse effects such as:

• Extrapyramidal symptoms
• Hyperprolactinemia
• Sedation
• Tachycardia

---

Why Patients Begin Looking for Alternatives

While paliperidone can stabilize symptoms, many patients eventually ask:

• Can the underlying condition be improved?
• Is there a way to reduce medication burden?

Because the key limitation is:

👉 the drug primarily controls symptoms, not the underlying biological dysfunction

---

Perspectiva Moderna: Beyond Symptom Control

Nos últimos anos, psychiatry has increasingly focused on deeper mechanisms such as:

• Neuroinflammation
• Brain microcirculation
• Cellular metabolism

This has led to growing interest in:

👉 medicina regenerativa

---

The Role of Mesenchymal Stem Cells

Pergunta: Why are stem cells being explored in neurological conditions?
Responder:

Mesenchymal stem cells may:

• Modulate neuroinflammation
• Improve cerebral blood flow
• Support cellular repair processes
• Influence overall brain environment

This represents a fundamentally different approach compared to pharmacological suppression of symptoms.

---

Where These Treatments Are Available

Na Europa, a medicina regenerativa é cada vez mais implementada em ambientes clínicos especializados.

Em particular, Barcelona, Espanha, tornou-se um dos principais locais onde:

• Células-tronco mesenquimais autólogas são usadas
• Os protocolos de tratamento são individualizados
• Estratégias de dosagem controlada são aplicadas
• Medical supervision is maintained

---

Treatment Strategy: Controlled and Gradual Approach

Modern regenerative protocols often include:

• Around 10 million mesenchymal stem cells per session
• Intravenous administration
• Multiple sessions over time

This allows gradual biological adaptation rather than abrupt changes.

---

Important Medical Clarification

Stem cell therapy does not replace psychiatric medication immediately.

Em vez de, it may be considered:

👉 a complementary strategy in complex or long-term cases

---

Transition to Detailed Drug Information

Below you will find detailed information about paliperidone (Invega), including side effects, patient experiences, and clinical use.

Paliperidone, sold under the trade name Invega among others, is an atypical antipsychotic. It is mainly used to treat schizophrenia and schizoaffective disorder.

It is marketed by Janssen Pharmaceuticals. An extended release formulation is available that uses the OROS extended release system to allow for once-daily dosing. Paliperidone palmitate is a long-acting injectable formulation of paliperidone palmitoyl ester indicated for once-every 28 days injection after an initial titration period.

Uso médico
It is used for the treatment of schizophrenia and schizoaffective disorder. [4]

Paliperidone palmitate long-acting injection compared to risperidone for schizophrenia[5]
When flexibly dosed every four weeks, paliperidone palmitate appears comparable in efficacy and tolerability to risperidone. In short-term studies, paliperidone palmitate – the longer-acting injection – has a similar adverse effect profile to related compounds such as risperidone by mouth. No difference was found in the high rate of reported adverse sexual outcomes and paliperidone palmitate is associated with an increase in serum prolactin.[5]
Outcome Findings in words Findings in numbers Quality of evidence
Adverse effects
Sources:

Very Common (>10% incidence)
Dor de cabeça
Tachycardia
Somnolence (causes less sedation than most atypical antipsychotics)[4]
Insomnia
Hyperprolactinaemia (seems to cause comparable prolactin elevation to its parent drug, risperidone)[4]
Sexual Dysfunction
Common (1–10% incidence)
Cough
Extrapyramidal side effects (EPSE; e.g. dystonia, akathisia, muscle rigidity, parkinsonism. It appears to produce similar EPSE to risperidone, asenapine and ziprasidone and more EPSE than olanzapine, clozapine, aripiprazole, quetiapine, amisulpride and sertindole)[4]
Orthostatic hypotension
Weight gain (tends to produce a moderate degree of weight gain, possibly related to its potent blockade of the 5-HT2C receptor)
QT interval prolongation (tends to produce less QT interval prolongation than most other atypical antipsychotics and approximately as much QT interval prolongation as aripiprazole and lurasidone)[4]
Nasopharyngitis
Anxiety
Indigestion
Constipation
Descontinuação
O Formulário Nacional Britânico recomenda uma retirada gradual ao interromper os antipsicóticos para evitar síndrome de abstinência aguda ou recaída rápida.[11] Os sintomas de abstinência geralmente incluem náusea, vômito, e perda de apetite.[12] Outros sintomas podem incluir inquietação, aumento da sudorese, e dificuldade para dormir.[12] Menos comumente, pode haver uma sensação de que o mundo está girando, dormência, ou dores musculares.[12] Os sintomas geralmente desaparecem após um curto período de tempo.[12]

Há evidências provisórias de que a descontinuação dos antipsicóticos pode resultar em psicose.[13] Também pode resultar na recorrência da doença que está sendo tratada.[14] Raramente pode ocorrer discinesia tardia quando a medicação é interrompida.[12]

Deaths
Em abril 2014, it was reported that 21 Japanese people who had received shots of the long-acting injectable paliperidone to date had died, out of 10,700 individuals prescribed the drug.[15][16][17][18][19][20][21]

Farmacologia
Paliperidone[22]
Site Ki (nM)
5-HT1A 617
5-HT2A 1.1
5-HT2C 48
5-HT7 2.7
α1A 2.5
α2A 3.9
α2C 2.7
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.
Paliperidone is the primary active metabolite of the older antipsychotic risperidone.[23] While its specific mechanism of action is unknown, it is believed paliperidone and risperidone act via similar, if not identical, pathways.[22] Its efficacy is believed to result from central dopaminergic and serotonergic antagonism. Food is known to increase the absorption of Invega type ER OROS prolonged-release tablets. Food increased exposure of paliperidone by up to 50-60%, no entanto, half-life was not significantly affected. The effect was probably due to a delay in the transit of the ER OROS formulation in the upper part of the GI channel, resulting in increased absorption.[24]

The half-life is 23 hours.[24]

Risperidone and its metabolite paliperidone are reduced in efficacy by P-glycoprotein inducers such as St John’s wort[25][26]

vte Pharmacokinetics of long-acting injectable antipsychotics
História
Paliperidone (as Invega) was approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia in 2006. Paliperidone was approved by the FDA for the treatment of schizoaffective disorder in 2009. The long-acting injectable form of paliperidone, marketed as Invega Sustenna in U.S. and Xeplion in Europe, was approved by the FDA on July 31, 2009. It is the only available brand in Bangladesh under the brand name “Palimax ER” manufactured & marketed by ACI Pharmaceuticals.

It was initially approved in Europe in 2007 for schizophrenia, the extended release form and use for schizoaffective disorder were approved in Europe in 2010, and extension to use in adolescents older than 15 years old was approved in 2014.[37]

Brand names
On May 18, 2015, a new formulation of paliperidone palmitate was approved by the FDA under the brand name Invega Trinza.[38] A similar 3 -monthly injection of prolonged release suspension was approved in 2016 by the European Medicines Agency originally under the brand name Paliperidone Janssen, later renamed to Trevicta.[39]

Modern Treatment Perspective

While medications like paliperidone remain essential in psychiatric care, there is growing interest in approaches that address deeper biological mechanisms.

Na Europa, incluindo Barcelona, Espanha, terapias regenerativas usando células-tronco mesenquimais autólogas are being explored in structured clinical settings.

These approaches aim to:

• Support brain function
• Melhorar o equilíbrio sistêmico
• Reduce chronic inflammation

This reflects a broader shift in medicine:

👉 from symptom control → to functional and biological restoration

---

Palavras-chave :

paliperidone invega side effects, invega long term risks, paliperidone injection side effects, tardive dyskinesia antipsychotics, mesenchymal stem cells psychiatry Barcelona Spain, regenerative treatment schizophrenia Europe